SAN DIEGO, May 20, 2015 /PRNewswire/ -- OncoSec Medical
Inc. ("OncoSec") (OTCQB: ONCSD), a company developing DNA-based
intratumoral cancer immunotherapies, will present data from ongoing
clinical and preclinical studies at the New York Academy of
Sciences' Emerging Approaches to Cancer Immunotherapy. OncoSec's
Chief Scientific Officer Robert H.
Pierce, MD, and Chief Medical Officer Mai. H. Le, MD, will
present an abstract entitled: "Intratumoral Expression of Plasmid
IL-12 Can Increase CD8 TILs and Drive Systemic Anti-Tumor
Responses: Rationale for Combination with Anti-PD-1 Blockade" as
part of a poster presentation beginning at 12:10 PM ET on Thursday,
May 21, 2015 in New York
City.
The poster presentation will discuss the unmet medical need of
"anti-PD-1 non-responders," which are characterized by the absence
of immune cells, and the role of interventions that are
specifically focused on increasing tumor-infiltrating lymphocytes
(TILs). By increasing TILs and promoting tumor immunogenicity,
these interventions may convert anti-PD-1 non-responders to
responders. Intratumoral electroporation-mediated gene therapy with
DNA-based IL-12 has demonstrated single-agent anti-tumor efficacy
in both preclinical tumor models as well as Phase I and II clinical
trials in advanced melanoma. The data highlighted in this
presentation suggest that intratumoral delivery of DNA-based IL-12
followed by electroporation can increase CD8 TILs, promote tumor
immunogenicity, drive systemic anti-tumor responses, and increase
the patient population who may benefit from therapeutic PD-1/PD-L1
blockade.
Abstract information is as follows:
- Title: Intratumoral Expression of Plasmid IL-12 Can Increase
CD8 TILs and Drive Systemic Anti-Tumor Responses: Rationale for
Combination with Anti-PD-1 Blockade
- Presenters: Robert H. Pierce,
MD; Mai. H. Le, MD
- Time/Date: 12:10 PM ET,
Thursday, May 21, 2015
- Location: The New York Academy of Sciences
About Emerging Approaches to Cancer Immunotherapy
Emerging Approaches to Cancer Immunotherapy is hosted by the New
York Academy of Sciences to bring together leading experts in
immunotherapy and immunology to discuss emerging approaches, along
with the challenges and opportunities faced in this evolving field.
Over the past several years, cancer immunotherapy has made progress
both conceptually and in clinical practice. Led by landmark studies
in the setting of metastatic melanoma, many of the findings of this
field are being generalized both to hematological malignancies and
to other solid tumors. Areas of investigation such as checkpoint
blockade inhibitors, advanced tumor vaccination studies, and
adoptive T-cell therapies are changing the face of cancer
treatment, and will be discussed at the upcoming meeting. For more
information, please visit: www.nyas.org.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a
biopharmaceutical company developing its investigational
ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core
technology is designed to enhance the local delivery and uptake of
DNA IL-12 and other DNA-based immune-targeting agents. Clinical
studies of ImmunoPulse™ have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response limiting the systemic
toxicities associated with other treatments. OncoSec's lead program
evaluating ImmunoPulse™ for the treatment of metastatic melanoma is
currently in Phase II development, and is being conducted in
collaboration with several prominent academic medical centers. As
the company continues to evaluate ImmunoPulse™ in its current
indications, it is also focused on identifying and developing new
immune-targeting agents, investigating additional tumor
indications, and evaluating combination-based immunotherapy
approaches. For more information, please visit www.oncosec.com.
OncoSec Medical Inc. Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-medical-to-present-data-at-the-new-york-academy-of-sciences-cancer-immunotherapy-symposium-300086308.html
SOURCE OncoSec Medical Inc.